Showing results (71-80 of 86) with videos related to
Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup AnalysesHans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2024
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple MyelomaNaresh Bumma, Joshua Richter, Sundar Jagannath, et al.Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.Research Square|May 5, 2025
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple MyelomaRafael Renatino Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.Pageof 9